We are a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. We are a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence.
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer PR Newswire SAN DIEGO, Jan. 21, 2025 SAN DIEGO, Jan. 21, 2025...
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance PR Newswire SAN DIEGO, Jan. 13, 2025 SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the...
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results PR Newswire SAN DIEGO, Nov. 14, 2024 SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx...
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation PR Newswire SAN DIEGO, Nov. 4, 2024 SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc...
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO, Aug. 13, 2024 SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Inhibrx...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.63 | 4.86486486486 | 12.95 | 14.125 | 11.79 | 115061 | 13.01369446 | CS |
4 | -1.73 | -11.2998040496 | 15.31 | 16.83 | 11.79 | 89299 | 13.68469968 | CS |
12 | -2.57 | -15.9133126935 | 16.15 | 17.41 | 11.79 | 82826 | 14.41653048 | CS |
26 | -0.65 | -4.56781447646 | 14.23 | 17.79 | 10.8 | 88094 | 14.67058319 | CS |
52 | -25.03 | -64.8277648278 | 38.61 | 39.79 | 10.8 | 283778 | 29.44373769 | CS |
156 | -11.45 | -45.745105873 | 25.03 | 39.79 | 7.67 | 419456 | 24.91706561 | CS |
260 | -6.12 | -31.0659898477 | 19.7 | 50.97 | 7.67 | 337195 | 25.80950303 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.